Blood Journal
Leading the way in experimental and clinical research in hematology

Moreau P, Attal M, Pégourié B, et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood. 2011;117(11):3041–3044.

On page 3043 in the 17 March 2011 issue, there are errors in the Figure 1 legend; the P values are correct. The corrected legend sections should have read as listed below. The corrected Figure 1 legend is shown.

  1. achievement of VGPR after induction versus < VGPR

  2. correct

  3. achievement of VGPR after induction in VAD and bortezomib-dexamethasone arms versus < VGPR

  4. correct

  5. correct

  6. achievement of VGPR after induction in ISS stages 2 and 3 versus < VGPR

  7. achievement of VGPR after induction in poor-risk cytogenetics versus < VGPR

Figure 1. Progression-free survival. (A) Achievement of VGPR after induction therapy versus < VGPR; (B) achievement of VGPR after induction versus after high-dose therapy; (C) achievement of VGPR after induction in VAD and bortezomib-dexamethasone arms versus < VGPR; (D) ISS stages 2 and 3, bortezomib-dexamethasone induction versus VAD; (E) poor-risk cytogenetics, bortezomib-dexamethasone induction versus VAD; (F) achievement of VGPR after induction in ISS stages 2 and 3 versus < VGPR; (G) achievement of VGPR after induction in poor-risk cytogenetics versus < VGPR. (A) P < .0001; (B) P = .01; (C) P < .0001; (D) P = .006; (E) P = .11; (F) P < .0001; and (G) P = .0036.